Sumedha Sudhaman
Research Subjects
Sumedha Sudhaman has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Levine
Arthur and Sonia Labbatt Brain Tumor Research Center, Hospital for Sick Children (SickKids) , Toronto, ON
46 shared publications - Anirban Das
Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada
46 shared publications - Ayse Bahar Ercan
Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada
46 shared publications - Birgit Ertl-Wagner
The Hospital for Sick Children
46 shared publications - Cynthia Hawkins
Division of Pathology, The Hospital for Sick Children, Toronto, Canada
46 shared publications - Daniel A. Morgenstern
Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
46 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Distribution of lead time between ctDNA detection and imaging-confirmed recurrence using the first ctDNA-positive sample prior to recurrence. Each dot represents an individual patient with green dots representing patients who became ctDNA-positive and whose initial post-positivity imaging remained negative with recurrence confirmed on subsequent imaging.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Distribution of lead time between ctDNA detection and imaging-confirmed recurrence using the first ctDNA-positive sample prior to recurrence. Each dot represents an individual patient with green dots representing patients who became ctDNA-positive and whose initial post-positivity imaging remained negative with recurrence confirmed on subsequent imaging.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
A, Kaplan–Meier RFS curves stratified by ctDNA status among patients who received adjuvant systemic therapy. Anytime ctDNA positivity was associated with significantly inferior RFS. B, Kaplan–Meier RFS curves stratified by ctDNA status among patients who did not receive adjuvant therapy, showing a similar strong association between ctDNA positivity and recurrence. C, Sankey diagram illustrating ctDNA dynamics after systemic therapy initiation among 53 patients with ≥1 on-treatment ctDNA timepoint. Of the 8 patients who recurred, 2 exhibited persistent ctDNA positivity or converted from ctDNA-negative to ctDNA-positive despite treatment. A subset demonstrated transient clearance before recurrence.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
A, Kaplan–Meier RFS curves stratified by ctDNA status among patients who received adjuvant systemic therapy. Anytime ctDNA positivity was associated with significantly inferior RFS. B, Kaplan–Meier RFS curves stratified by ctDNA status among patients who did not receive adjuvant therapy, showing a similar strong association between ctDNA positivity and recurrence. C, Sankey diagram illustrating ctDNA dynamics after systemic therapy initiation among 53 patients with ≥1 on-treatment ctDNA timepoint. Of the 8 patients who recurred, 2 exhibited persistent ctDNA positivity or converted from ctDNA-negative to ctDNA-positive despite treatment. A subset demonstrated transient clearance before recurrence.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Representativeness of the study participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Representativeness of the study participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIIA melanoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIIA melanoma.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIB melanoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIB melanoma.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIA melanoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIA melanoma.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Flow diagram depiction of ctDNA-driven changes in clinical management with representative case examples. Of the 190 patients included in our study, 34 had ctDNA positivity at any time point. Of these, clinical care was influenced by ctDNA positivity in 26 cases, ranging from imaging escalation to treatment initiation, switch, or escalation. MTM, mean tumor molecules; ND, not detected; NED, no evidence of disease; PR, partial response.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Flow diagram depiction of ctDNA-driven changes in clinical management with representative case examples. Of the 190 patients included in our study, 34 had ctDNA positivity at any time point. Of these, clinical care was influenced by ctDNA positivity in 26 cases, ranging from imaging escalation to treatment initiation, switch, or escalation. MTM, mean tumor molecules; ND, not detected; NED, no evidence of disease; PR, partial response.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IA/B melanoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IA/B melanoma.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIC melanoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIC melanoma.